depression treatment

GH Research PLC (NASDAQ: GHRS) has reported the outcome of the Phase 2 part of a Phase 1/2 trial of GH001, an inhalable 5-MeO-DMT product candidate for treatment-resistant depression (TRD). The trial met its primary endpoint with 7 of 8 patients (87.5%) in remission at day 7 after...

Pasithea Therapeutics Corp's (NASDAQ: KTTA) wholly-owned subsidiary, Pasithea Clinics, has been approved to provide esketamine nasal spray (Spravato) for treatment-resistant depression (TRD) in adults. Related Link: EXCLUSIVE: Pasithea Administers First IV Ketamine Infusion Therapy In...

The FDA has cleared BrainsWay Ltd's (NASDAQ: BWAY) Deep Transcranial Magnetic Stimulation (Deep TMS) System to reduce comorbid anxiety symptoms in adult patients with depression, also known as anxious depression. BrainsWay submitted data from 573 patients in support of its...

Praxis Precision Medicines Inc (NASDAQ: PRAX) has reported results from its PRAX-114 Phase 2a Part B proof-of-concept trial for perimenopausal depression (PMD). PRAX-114 60 mg suspension formulation (n=6) for 14 days in an outpatient setting showed rapid and sustained improvements...

Peter Thiel-backed Atai Life Sciences (NASDAQ: ATAI) has launched a new portfolio company, Revixia Life Sciences. Revixia Life's primary mission is to develop Salvinorin A (SalA) to treat various mental health disorders. Derived from Salvia divinorum, SalA is a non-...